Headlines about Iovance Biotherapeutics (NASDAQ:IOVA) have trended somewhat negative on Saturday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Iovance Biotherapeutics earned a media sentiment score of -0.02 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.8058307575383 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s scoring:
IOVA has been the topic of several recent analyst reports. BidaskClub lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. ValuEngine raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. HC Wainwright increased their target price on shares of Iovance Biotherapeutics from $16.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, January 25th. Oppenheimer increased their target price on shares of Iovance Biotherapeutics from $13.00 to $19.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Finally, Jefferies Group increased their target price on shares of Iovance Biotherapeutics to $31.00 and gave the stock a “buy” rating in a research note on Friday, February 9th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $19.72.
IOVA opened at $13.85 on Friday. Iovance Biotherapeutics has a twelve month low of $4.45 and a twelve month high of $19.90. The stock has a market cap of $1,346.16, a P/E ratio of -9.82 and a beta of 5.75.
Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.04). analysts forecast that Iovance Biotherapeutics will post -1.25 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/somewhat-negative-news-coverage-somewhat-unlikely-to-impact-iovance-biotherapeutics-iova-stock-price.html.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.